Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: A meta-analysis of non-family-based studies

Autoimmunity Reviews

Volumn 10, Issue 8, 2011, Pages 474-481

  Zhang, Qiong ^a,b   Lin, Chun Ying ^a   Dong, Qiang ^b   Wang, Jian ^b   Wang, Wei ^c  

^a Nanhui Central Hospital   (China)

^b FUDAN UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Caucasian; HLA DR antigen; Meta analysis; Multiple sclerosis; Relatively predispositional effect method

Indexed keywords

HLA DR ANTIGEN;

ALLELE; AUTOIMMUNE DISEASE; CASE CONTROL STUDY; CAUCASIAN; GENE FREQUENCY; GENE TARGETING; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GENETIC SUSCEPTIBILITY; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; PHENOTYPE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; CHINA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; RISK;

EID: 79957649464     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.03.003     Document Type: Review

References (83)

1. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007, 357:851-862.
2. Winchester R., Ebers G., Fu S.M., Espinosa L., Zabriskie J., Kunkel H.G. B-cell alloantigen Ag 7a in multiple sclerosis. Lancet 1975, 2:814.
3. Fogdell A., Hillert J., Sachs C., Olerup O. The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5 0101 allele. Tissue Antigens 1995, 46:333-336.
4. Dyment D.A., Ebers G.C., Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol 2004, 3:104-110.
5. Tobon G.J., Youinou P., Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 2010, 9:A288-A292.
6. Meyer N., Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 2010, 9:A379-A382.
7. Oliveira L.C., Porta G., Marin M.L., Bittencourt P.L., Kalil J., Goldberg A.C. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev 2010.
8. Jacobson E.M., Huber A., Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun 2008, 30:58-62.
9. Feldman B.M., Rider L.G., Reed A.M., Pachman L.M. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371:2201-2212.
10. Rojas-Villarraga A., Botello-Corzo D., Anaya J.M. HLA-Class II in Latin American patients with type 1 diabetes. Autoimmun Rev 2010, 9:666-673.
11. Borchers A.T., Uibo R., Gershwin M.E. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010, 9:A355-A365.
12. Hillert J. Human leukocyte antigen studies in multiple sclerosis. Ann Neurol 1994, 36(Suppl):S15-S17.
13. Schmidt H., Williamson D., Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol 2007, 165:1097-1109.
14. Kaushansky N., Eisenstein M., Zilkha-Falb R., Ben-Nun A. The myelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis. Autoimmun Rev 2010, 9:233-236.
15. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006, 15:2813-2824.
16. Dyment D.A., Herrera B.M., Cader M.Z., Willer C.J., Lincoln M.R., Sadovnick A.D., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005, 14:2019-2026.
17. Stankovich J., Butzkueven H., Marriott M., Chapman C., Tubridy N., Tait B.D., et al. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens 2009, 74:17-21.
18. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000, 48:211-219.
19. McDonnell G.V., Mawhinney H., Graham C.A., Hawkins S.A., Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci 1999, 165:77-83.
20. Rasmussen H.B., Kelly M.A., Clausen J. Additive effect of the HLA-DR15 haplotype on susceptibility to multiple sclerosis. Mult Scler 2001, 7:91-93.
21. Rojas O.L., Rojas-Villarraga A., Cruz-Tapias P., Sanchez J.L., Suarez-Escudero J.C., Patarroyo M.A., et al. HLA class II polymorphism in Latin American patients with multiple sclerosis. Autoimmun Rev 2010, 9:407-413.
22. Alves-Leon S.V., Papais-Alvarenga R., Magalhaes M., Alvarenga M., Thuler L.C., Fernandez y Fernandez O. Ethnicity-dependent association of HLA DRB1-DQA1-DQB1 alleles in Brazilian multiple sclerosis patients. Acta Neurol Scand 2007, 115:306-311.
23. Wu X.M., Wang C., Zhang K.N., Lin A.Y., Kira J., Hu G.Z., et al. Association of susceptibility to multiple sclerosis in Southern Han Chinese with HLA-DRB1, -DPB1 alleles and DRB1-DPB1 haplotypes: distinct from other populations. Mult Scler 2009, 15:1422-1430.
24. Kelly M.A., Jacobs K.H., Penny M.A., Mijovic C.H., Nightingale S., Barnett A.H., et al. An investigation of HLA-encoded genetic susceptibility to multiple sclerosis in subjects of Asian Indian and Afro-Caribbean ethnic origin. Tissue Antigens 1995, 45:197-202.
25. Kelly M.A., Zhang Y., Penny M.A., Jacobs K.H., Cavan D.A., Mijovic C.H., et al. Genetic susceptibility to multiple sclerosis in a Shanghai Chinese population. The role of the HLA class II genes. Hum Immunol 1995, 42:203-208.
26. Holdsworth R., Hurley C.K., Marsh S.G., Lau M., Noreen H.J., Kempenich J.H., et al. The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Tissue Antigens 2009, 73:95-170.
27. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
28. Payami H., Joe S., Farid N.R., Stenszky V., Chan S.H., Yeo P.P., et al. Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease. Am J Hum Genet 1989, 45:541-546.
29. Ghabanbasani M.Z., Gu X.X., Spaepen M., Vandevyver C., Raus J., Marynen P., et al. Importance of HLA-DRB1 and DQA1 genes and of the amino acid polymorphisms in the functional domain of DR beta 1 chain in multiple sclerosis. J Neuroimmunol 1995, 59:77-82.
30. Dean G., Yeo T.W., Goris A., Taylor C.J., Goodman R.S., Elian M., et al. HLA-DRB1 and multiple sclerosis in Malta. Neurology 2008, 70:101-105.
31. Harbo H.F., Lie B.A., Sawcer S., Celius E.G., Dai K.Z., Oturai A., et al. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 2004, 63:237-247.
32. Boiko A.N., Gusev E.I., Sudomoina M.A., Alekseenkov A.D., Kulakova O.G., Bikova O.V., et al. Association and linkage of juvenile MS with HLA-DR2(15) in Russians. Neurology 2002, 58:658-660.
33. Allcock R.J., de la Concha E.G., Fernandez-Arquero M., Vigil P., Conejero L., Arroyo R., et al. Susceptibility to multiple sclerosis mediated by HLA-DRB1 is influenced by a second gene telomeric of the TNF cluster. Hum Immunol 1999, 60:1266-1273.
34. Brum D.G., Barreira A.A., Louzada-Junior P., Mendes-Junior C.T., Donadi E.A. Association of the HLA-DRB1 15 allele group and the DRB1 1501 and DRB1 1503 alleles with multiple sclerosis in White and Mulatto samples from Brazil. J Neuroimmunol 2007, 189:118-124.
35. Link J., Lorentzen A.R., Kockum I., Duvefelt K., Lie B.A., Celius E.G., et al. Two HLA class I genes independently associated with multiple sclerosis. J Neuroimmunol 2010, 226:172-176.
36. Romero-Pinel L., Pujal J.M., Martinez-Yelamos S., Gubieras L., Matas E., Bau L., et al. HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population. Eur J Neurol 2010.
37. Zipp F., Windemuth C., Pankow H., Dichgans J., Wienker T., Martin R., et al. Multiple sclerosis associated amino acids of polymorphic regions relevant for the HLA antigen binding are confined to HLA-DR2. Hum Immunol 2000, 61:1021-1030.
38. Coraddu F., Reyes-Yanez M.P., Parra A., Gray J., Smith S.I., Taylor C.J., et al. HLA associations with multiple sclerosis in the Canary Islands. J Neuroimmunol 1998, 87:130-135.
39. Patrucco L., Larriba J., Redal M.A., Rojas J.I., Argibay P.F., Cristiano E. HLA-DRB1 and multiple sclerosis in Argentina. Eur J Neurol 2009, 16:427-429.
40. Ballerini C., Guerini F.R., Rombola G., Rosati E., Massacesi L., Ferrante P., et al. HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe. J Neuroimmunol 2004, 150:178-185.
41. Ciusani E., Allen M., Sandberg-Wollheim M., Eoli M., Salmaggi A., Milanese C., et al. Analysis of HLA-class II DQA1, DQB1, DRB1 and DPB1 in Italian multiple sclerosis patients. Eur J Immunogenet 1995, 22:171-178.
42. Epplen C., Jackel S., Santos E.J., D'Souza M., Poehlau D., Dotzauer B., et al. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol 1997, 41:341-352.
43. Fernandez O., Fernandez V., Alonso A., Caballero A., Luque G., Bravo M., et al. DQB1 0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J Neurol 2004, 251:440-444.
44. Silva A.M., Pereira C., Bettencourt A., Carvalho C., Couto A.R., Leite M.I., et al. The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population. J Neurol Sci 2007, 258:69-74.
45. DeLuca G.C., Ramagopalan S.V., Herrera B.M., Dyment D.A., Lincoln M.R., Montpetit A., et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA 2007, 104:20896-20901.
46. Wu J.S., James I., Wei Q., Castley A., Christiansen F.T., Carroll W.M., et al. Influence of HLA-DRB1 allele heterogeneity on disease risk and clinical course in a West Australian MS cohort: a high-resolution genotyping study. Mult Scler 2010, 16:526-532.
47. Fernandez-Morera J.L., Rodriguez-Rodero S., Tunon A., Martinez-Borra J., Vidal-Castineira J.R., Lopez-Vazquez A., et al. Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibility. Tissue Antigens 2008, 72:54-59.
48. Montanaro D., Sanna V., Matarese G., Larby B.B., Racioppi L., Carrieri P.B., et al. The fine specificity of human T cell lines towards myelin basic protein peptides in southern Italian multiple sclerosis patients. Clin Exp Immunol 2001, 123:288-293.
49. Cullen C.G., Middleton D., Savage D.A., Hawkins S. HLA-DR and DQ DNA genotyping in multiple sclerosis patients in Northern Ireland. Hum Immunol 1991, 30:1-6.
50. Francis D.A., Thompson A.J., Brookes P., Davey N., Lechler R.I., McDonald W.I., et al. Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ?. Hum Immunol 1991, 32:119-124.
51. Luomala M., Elovaara I., Ukkonen M., Koivula T., Lehtimaki T. The combination of HLA-DR1 and HLA-DR53 protects against MS. Neurology 2001, 56:383-385.
52. Greer J.M., Pender M.P. The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis. J Neurol Neurosurg Psychiatry 2005, 76:656-662.
53. Guerini F.R., Ferrante P., Losciale L., Caputo D., Lombardi M.L., Pirozzi G., et al. Myelin basic protein gene is associated with MS in DR4- and DR5-positive Italians and Russians. Neurology 2003, 61:520-526.
54. Perini P., Tagliaferri C., Belloni M., Biasi G., Gallo P. The HLA-DR13 haplotype is associated with "benign" multiple sclerosis in northeast Italy. Neurology 2001, 57:158-159.
55. Zivadinov R., Uxa L., Zacchi T., Nasuelli D., Ukmar M., Furlan C., et al. HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol 2003, 250:1099-1106.
56. Pina M.A., Ara J.R., Lasierra P., Modrego P.J., Larrad L. Study of HLA as a predisposing factor and its possible influence on the outcome of multiple sclerosis in the sanitary district of Calatayud, northern Spain. Neuroepidemiology 1999, 18:203-209.
57. Weatherby S.J., Thomson W., Pepper L., Donn R., Worthington J., Mann C.L., et al. HLA-DRB1 and disease outcome in multiple sclerosis. J Neurol 2001, 248:304-310.
58. Weinshenker B.G., Santrach P., Bissonet A.S., McDonnell S.K., Schaid D., Moore S.B., et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998, 51:742-747.
59. Stewart G.J., Teutsch S.M., Castle M., Heard R.N., Bennetts B.H. HLA-DR, -DQA1 and -DQB1 associations in Australian multiple sclerosis patients. Eur J Immunogenet 1997, 24:81-92.
60. Hillert J., Olerup O. Multiple sclerosis is associated with genes within or close to the HLA-DR-DQ subregion on a normal DR15, DQ6, Dw2 haplotype. Neurology 1993, 43:163-168.
61. Haegert D.G., Swift F.V., Benedikz J. Evidence for a complex role of HLA class II genotypes in susceptibility to multiple sclerosis in Iceland. Neurology 1996, 46:1107-1111.
62. Allen M., Sandberg-Wollheim M., Sjogren K., Erlich H.A., Petterson U., Gyllensten U. Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum Immunol 1994, 39:41-48.
63. Marrosu M.G., Murru M.R., Costa G., Cucca F., Sotgiu S., Rosati G., et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am J Hum Genet 1997, 61:454-457.
64. Ramagopalan S.V., Morris A.P., Dyment D.A., Herrera B.M., DeLuca G.C., Lincoln M.R., et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 2007, 3:1607-1613.
65. Marrosu M.G., Murru R., Murru M.R., Costa G., Zavattari P., Whalen M., et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum Mol Genet 2001, 10:2907-2916.
66. Donaldson P.T., Doherty D.G., Hayllar K.M., McFarlane I.G., Johnson P.J., Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991, 13:701-706.
67. Strettell M.D., Donaldson P.T., Thomson L.J., Santrach P.J., Moore S.B., Czaja A.J., et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997, 112:2028-2035.
68. Montano-Loza A.J., Carpenter H.A., Czaja A.J. Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis. Liver Int 2006, 26:1201-1208.
69. Heward J.M., Allahabadia A., Daykin J., Carr-Smith J., Daly A., Armitage M., et al. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. J Clin Endocrinol Metab 1998, 83:3394-3397.
70. Zamani M., Spaepen M., Bex M., Bouillon R., Cassiman J.J. Primary role of the HLA class II DRB1 0301 allele in Graves disease. Am J Med Genet 2000, 95:432-437.
71. Kong Y.C., Jacob J.B., Flynn J.C., Elliott B.E., Wei W.Z. Autoimmune thyroiditis as an indicator of autoimmune sequelae during cancer immunotherapy. Autoimmun Rev 2009, 9:28-33.
72. Mamyrova G., O'Hanlon T.P., Monroe J.B., Carrick D.M., Malley J.D., Adams S., et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006, 54:3979-3987.
73. Szodoray P., Szabo Z., Kapitany A., Gyetvai A., Lakos G., Szanto S., et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010, 9:140-143.
74. Deretzi G., Kountouras J., Koutlas E., Zavos C., Polyzos S., Rudolf J., et al. Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Mult Scler 2010, 16:1091-1101.
75. Somers E.C., Thomas S.L., Smeeth L., Hall A.J. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder?. Am J Epidemiol 2009, 169:749-755.
76. Middleton D., Menchaca L., Rood H., Komerofsky R. New allele frequency database. Tissue Antigens 2003, 61:403-407. http://www.allelefrequencies.net.
77. Isobe N., Matsushita T., Yamasaki R., Ramagopalan S.V., Kawano Y., Nishimura Y., et al. Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. Mult Scler 2010, 16:147-155.
78. Ebringer A., Rashid T., Wilson C. Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper. Autoimmun Rev 2010, 9:216-223.
79. Laaksonen M., Pastinen T., Sjoroos M., Kuokkanen S., Ruutiainen J., Sumelahti M.L., et al. HLA class II associated risk and protection against multiple sclerosis-a Finnish family study. J Neuroimmunol 2002, 122:140-145.
80. Mathieu A., Paladini F., Vacca A., Cauli A., Fiorillo M.T., Sorrentino R. The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. Autoimmun Rev 2009, 8:420-425.
81. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983, 13:227-231.
82. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
83. Messadi A., Najiba F.M., Ouerhani S., Zaweli J., Louatti I., Layouni S., et al. HLA class II alleles and multiple sclerosis in Tunisian patients. Clin Neurol Neurosurg 2010, 112:849-852.